Iodine-125 low-dose rate prostate brachytherapy.

Autor: Minami T; Department of Urology, Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan., Fujimoto S; Department of Urology, Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan., Fujita K; Department of Urology, Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan.
Jazyk: angličtina
Zdroj: International journal of urology : official journal of the Japanese Urological Association [Int J Urol] 2024 Oct 16. Date of Electronic Publication: 2024 Oct 16.
DOI: 10.1111/iju.15609
Abstrakt: Robotic-assisted laparoscopic radical prostatectomy and intensity-modulated radiation therapy are the most common radical treatments for localized prostate cancer, and brachytherapy (BT) also plays a role in this field. Iodine-125 (I-125) low-dose rate (LDR) prostate BT is an established treatment. However, it remains controversial. Specifically, there are a variety of issues, such as indications for combined treatment with external beam radiotherapy and androgen deprivation therapy, prostate-specific antigen follow-up, the significance of postimplant biopsy, the usefulness of salvage BT and focal therapy, reduction of toxicities, and bladder cancer after BT. In this review, we summarize the recent developments in I-125 LDR BT.
(© 2024 The Japanese Urological Association.)
Databáze: MEDLINE
Externí odkaz: